LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Status:
Completed
Trial end date:
2020-09-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the benefit of relugolix 40 milligrams (mg) once a
day co-administered with estradiol (E2) 1 mg and norethindrone acetate (NETA) 0.5 mg compared
with placebo for 24 weeks on heavy menstrual bleeding associated with uterine fibroids.